Get healthier,
together on optml
Clinical-trial results
Physician-led GLP-1 protocols, paired with nutrition and training, deliver weight-loss outcomes that diet and exercise alone consistently fall short of.
1SURMOUNT-1 (Jastreboff et al., NEJM 2022): tirzepatide 15 mg, −20.9% body weight at 72 weeks vs −3.1% placebo. 2STEP 1 (Wilding et al., NEJM 2021): semaglutide 2.4 mg, −14.9% body weight at 68 weeks vs −2.4% placebo. Adults with obesity or overweight plus a weight-related condition. Individual results vary.
Compounded-drug disclosure
Both trials studied the FDA-approved branded products (Zepbound®/Mounjaro®, Wegovy®/Ozempic®). OPTML prescribes compounded versions of the same active ingredients; compounded preparations are not FDA-approved, and the FDA does not verify the safety, effectiveness, or quality of compounded drugs.

LegitScript verified